2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Pathogenesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2390 Safety and efficacy of kq-2003, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory POEMS syndrome patients

Lu Zhang, M.D., Wanling Sun, MD, PhD2, Yu Wu3, Guoxiang Wu4, Dan Li5, Xing Xiao6, Jian Li, MD7
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Department of Hematology, Xuanwu Hospital, National Center for Neurological Disorders, Capital Medical University, Beijing, China
3 Department of Hematology, West China Hospital of Sichuan University, Chengdu, China
4 Novatim Immune Therapeutics (Zhejiang) Co., Ltd., Shanghai, China
5 Novatim Immune Therapeutics (Zhejiang) Co., Ltd., Shanghai, China
6 Novatim Immune Therapeutics (Zhejiang) Co., Ltd., Shanghai, China
7 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Introduction:
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes) is a rare and life-threatening syndrome due to an underlying plasma cell neoplasm. Treatment options for patients with relapsed or refractory (R/R) POEMS remain limited. KQ-2003 is a dual-targeting chimeric antigen receptor (CAR) T-cell therapy directed against B-cell maturation antigen (BCMA) and CD19, designed to achieve broad and durable eradication of the pathogenic plasma cell clone. Here, we report preliminary results from a phase ? study.

 Methods:
This open-label, single-arm, multicenter study conducted in China (NCT06518876) evaluated the safety, tolerability, and preliminary efficacy of KQ-2003 at two dose levels (DLs) in patients with R/R POEMS. Eligible patients were aged ≥18 years; had received prior treatment with a proteasome inhibitor and/or an immunomodulatory drug; had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, a serum vascular endothelial growth factor (VEGF) ≥1,200 ng/L, and an Overall Neuropathy Limitations Scale (ONLS) score ≥1; and had documented evidence of disease progression. Following lymphodepletion, patients received a single infusion of KQ-2003 at 0.5 × 10^6 cells/kg in DL1 or 1.0 × 10^6 cells/kg in DL2. Dose escalation and selection of the recommended phase 2 dose (RP2D) were guided by review of accumulating safety and efficacy data by the safety review committee (SRC). The primary objectives were to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) or RP2D; The secondary objectives were to assess preliminary efficacy and characterize the pharmaco-kinetic/pharmaco-dynamic (PK/PD) profiles. 

Results:
Nine patients received KQ-2003, including 3 pts at DL1 and 6 at DL2. The median age was 54 years (range 37–59), and 6 (66.7%) patients were male. The median time from diagnosis of to CAR T-cell infusion was 71 months (range, 14–146), and the median number of prior lines of therapy was 3 (range, 1–4). All patients had previously received an immunomodulatory drug; seven patients (77.8%) had received a proteasome inhibitor; one patient (11.1%) had received an anti-CD38 monoclonal antibody; and three patients (33.3%) had undergone prior autologous stem cell transplantation.

As of the data cutoff date of June 18, 2026, the median follow up was 9.6 (range 1.0-17.8) months. During follow-up, cytokine release syndrome (CRS) occurred in 88.9% (8/9) of patients, including Grade 1 CRS in five, Grade 2 CRS in two, and Grade 3 CRS in one. Other common treatment-emergent adverse events (TEAEs) of any grade were neutrophil count decreased (100%), white blood cell decreased (100%), lymphopenia (88.9%), thrombocytopenia (88.9%), anemia (88.9%). The most common Grade ≥3 TEAEs were neutrophil count decreased (100%), white blood cell decreased (100%), and lymphopenia (88.9%). One patient experienced Grade 4 immune effector cell-associated neurotoxicity syndrome (ICANS) and he unfortunately died from pneumonia 244 days after KQ-2003 infusion.

All nine patients achieved a serum VEGF complete response (CRV, ≤600ng/L). The first documented CRV occurred at Day 14 in 3 patients, at Day 28 in 5 patients, and at Month 6 in 1 patient. The longest ongoing duration of VEGF complete response was 17.8 months. Among the six patients with measurable serum M-protein at baseline, three (50.0%) achieved a hematologic complete response (CRH). CRH was first documented at Month 2 in one patient and at Month 9 in two patients. The hematologic CR rate was 50.0% in both DL1 (1 of 2 evaluable patients) and DL2 (2 of 4 evaluable patients). Two patients had PET/CT-detectable lesions at baseline and underwent post-treatment metabolic assessment; both achieved complete metabolic responses. Six patients had completed clinical response assessments before the data cutoff, including evaluation of ONLS score, papilledema, organomegaly, and other disease-related manifestations. Four of these six pts (66.7%) achieved a clinical response.

Pharmaco-kinetic analysis showed median Tmax of 13.7 days and median Cmax of 311,091.45 copies/μg gDNA in DL1. In DL2, the median Tmax was 9.8 days and the median Cmax was 287,314.5 copies/μg gDNA. No clear dose-dependent trend was identified.

Conclusion:
Preliminary phase I results demonstrated overall manageable safety profiles and promising efficacy profiles of KQ-2003 in patients with relapsed/refractory POEMS syndrome.

.

Lu Zhang, M.D.: No relevant conflicts of interest to declare.